Skip to main content
    S

    Sunshine Biopharma Inc (SBFM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $2.60
    -0.10 (-3.70%)

    Market Cap: $2.22M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Sunshine Biopharma Inc (SBFM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Sunshine Biopharma reported revenue of $36.31M for the fiscal year ended Dec 31, 2025, up 4.1% from the year before. That year, net income was -$5.98M with a net margin of -16.5%, operating cash flow was -$5.33M and free cash flow was -$5.51M. The quarter ended Sep 30, 2026 had revenue of $9.44M and net income of -$1.22M.

    Revenue and Margins

    The operating margin was -17.2% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $21.12K, a compound annual rate of 246.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$36.31M+4.1%33.8%-17.2%-16.5%
    Dec 2024$34.87M+44.7%30.6%-16.7%-14.7%
    Dec 2023$24.09M+454.4%34.6%-19.9%-18.7%
    Dec 2022$4.35M+1802.4%39.0%-621.3%-615.4%
    Dec 2021$228.43K+219.9%48.4%-1068.2%-5444.4%
    Dec 2020$71.41K+238.1%63.8%-807.8%-3898.7%
    Dec 2019$21.12KN/A47.7%-3037.9%-7860.9%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$36.31M$34.87M$24.09M$4.35M$228.43K$71.41K$21.12K$0$0$0
    Cost of revenue$24.05M$24.20M$15.75M$2.65M$117.83K$25.85K$11.05K$0$0$19.20K
    Gross profit$12.26M$10.67M$8.34M$1.70M$110.60K$45.56K$10.07K$0$0-$19.20K
    Research and development$604.31K$933.90K$1.86M$811.86K$672.21K$1.73K$15.20K$12.80K$0$32.79K
    Operating income-$6.23M-$5.81M-$4.79M-$27.00M-$2.44M-$576.87K-$641.64K-$1.16M-$857.19K-$993.11K
    Net income-$5.98M-$5.13M-$4.51M-$26.74M-$12.44M-$2.78M-$1.66M-$2.16M-$1.04M-$3.50M
    EBITDA-$5.90M-$5.63M-$4.64M-$26.98M-$2.43M-$554.92KN/A-$1.07M-$850.56KN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$9.44M$9.26M$8.09M$8.58M$9.42M$9.41M$8.90M$9.59M$8.44M$9.30M$7.54M$7.68M
    Gross profit$3.10M$2.43M$2.18M$3.03M$3.07M$3.42M$2.73M$3.09M$2.87M$2.36M$2.35M$2.57M
    Operating income-$1.29M-$1.61M-$1.40M-$1.79M-$1.09M-$2.05M-$1.30M-$2.09M-$1.11M-$1.27M-$1.35M-$1.16M
    Net income-$1.22M-$1.56M-$1.24M-$2.14M-$883.82K-$1.77M-$1.18M-$2.16M-$1.20M-$494.30K-$1.28M-$1.25M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $215.64K by $8.91M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$30.08M$30.56M$27.35M$29.24M$2.20M$1.05M$98.14K$1.15M$257.49K$64.40K
    Current assets$26.85M$25.97M$24.89M$27.31M$2.20M$1.03M$65.69K$1.10M$117.20K$58.46K
    Cash and equivalents$9.12M$9.69M$16.29M$21.83M$2.05M$989.89K$40.50K$110.53K$107.53K$57.45K
    Total liabilities$7.04M$7.06M$6.14M$7.62M$1.99M$2.00M$833.53K$1.20M$830.85K$274.10K
    Short-term debt$215.64K$207.76K$118.67K$123.03K$1.90M$964.12K$715.57K$662.76K$722.61K$236.97K
    Long-term debtN/AN/AN/AN/A$1.90M$949.01K$0$289.85K$79.71K$0
    Shareholder equity$23.04M$23.50M$21.21M$21.63M$211.66K-$954.84K-$735.38K-$55.75K-$573.36K-$209.70K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$33.86M$33.63M$27.93M$30.08M$31.49M$31.97M$29.19M$30.56M$30.06M$29.30M$31.90M$27.35M
    Total liabilities$5.22M$6.09M$6.41M$7.04M$7.29M$6.28M$6.48M$7.06M$5.02M$5.81M$7.08M$6.14M
    Cash and equivalents$14.62M$13.75M$6.91M$9.12M$9.31M$10.31M$8.12M$9.69M$12.21M$11.51M$17.43M$16.29M
    Shareholder equity$28.64M$27.54M$21.52M$23.04M$24.20M$25.68M$22.70M$23.50M$25.04M$23.49M$24.82M$21.21M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$5.33M-$12.52M-$8.78M-$5.25M-$1.83M-$657.30K-$495.80K-$512.81K-$543.52K-$314.18K
    Capital expenditures$174.49K$1.66M$82.25K$193.98K$0$1.19K$860$18.85K$3.72K$3.44K
    Free cash flow-$5.51M-$14.18M-$8.86M-$5.44M-$1.83M-$658.49K-$496.66K-$531.66K-$547.24K-$317.62K
    Share repurchases$0$3.14M$541.14K$99.00KN/AN/AN/AN/AN/AN/A
    Investing cash flow-$836.31K-$1.98M-$656.15K-$14.62M$0-$1.19K-$15.28K-$13.91K-$84.01K-$3.44K
    Financing cash flow$4.75M$8.94M$3.43M$39.47M$2.90M$1.61M$442.25K$527.64K$670.71K$324.62K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$917.98K-$2.07M-$1.62M-$727.80K-$1.27M-$1.70M-$3.41M-$1.36M-$4.58M-$3.19M-$2.69M-$457.29K
    Capital expenditures$7.01K$5.13K$1.04K$8.04K$160.00K$7.49K$102.60K$517.00K$974.51K$62.94K$382.36K$11.79K
    Free cash flow-$924.99K-$2.08M-$1.62M-$735.84K-$1.43M-$1.70M-$3.51M-$1.87M-$5.55M-$3.25M-$3.07M-$469.08K
    Last 12 quarters

    Frequently Asked Questions About SBFM

    What is Sunshine Biopharma's annual revenue?

    Sunshine Biopharma reported revenue of $36.31M for the fiscal year ended Dec 31, 2025.

    How fast is Sunshine Biopharma's revenue growing?

    Revenue was up 4.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 102.9%.

    Is Sunshine Biopharma profitable?

    No. Sunshine Biopharma reported net income of -$5.98M for the fiscal year ended Dec 31, 2025, with a net margin of -16.5%.

    How much free cash flow does SBFM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.33M minus capital expenditures of $174.49K produced free cash flow of -$5.51M.

    How much debt does Sunshine Biopharma have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $215.64K and cash and equivalents of $9.12M.